<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856137</url>
  </required_header>
  <id_info>
    <org_study_id>T1420</org_study_id>
    <nct_id>NCT04856137</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Diffuse Large B-cell Lymphoma</brief_title>
  <acronym>DLBL</acronym>
  <official_title>A Phase I/II Study of Relapse/Refractory Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shin Kong Wu Huo-Shih Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For continuous variables, mean, median, minimum, and maximum will be used for the descriptive&#xD;
      purpose. For categorical variables, frequency and percentage will be used for descriptive&#xD;
      statistics. The variables of OS will be estimated by the Kaplan-Meier method. Differences&#xD;
      between groups will be calculated using the log-rank test for univariate analysis. Cox's&#xD;
      proportional hazards model will be employed to test independent prognostic factors. All&#xD;
      calculations will be performed using the Statistical Package of Social Sciences software,&#xD;
      version 17.0 (SPSS, Inc., Chicago, IL, USA). The level of statistical significance will be&#xD;
      set at 0.05 for all tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single arm, prospective, multiple-center phase Ib/II study.&#xD;
&#xD;
      In phase Ib, a maximum of 18 patients will be enrolled in the dose-finding period to&#xD;
      determine the RP2D, dependent on the toxicity of the study drugs. The response rates of&#xD;
      salvage chemotherapy regimen in R/R DLBCL were reported to be within the range of 35-65%.3&#xD;
      Assuming that the response rate of traditional salvage therapy has an overall response rate&#xD;
      of 35% (H0=0.35) and that our experimental regimen would increase it to 50% (H1=0.50), the&#xD;
      estimated sample size according to the Simon's two-stage minimal design will be 49 in the&#xD;
      second phase.1 Briefly, among the 31 patients recruited during the first stage, the response&#xD;
      should be seen in at least 10 of the cases, the lowest threshold for the trial to be moved&#xD;
      into the second stage of the phase II part. Furthermore, for the RPR regimen to be deemed&#xD;
      effective, a response must be demonstrated in at least 21 of the whole 49 patients enrolled&#xD;
      in the phase II period. This would achieve a power of 80%, with a two-sided type I error rate&#xD;
      of 10%. An additional 7 patients will be recruited, for an estimated dropout rate of 10%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase Ib Dose Escalation&#xD;
All patients received:&#xD;
Rituximab 375mg/m2 on D1 of each cycle, and Paclitaxel 200mg/m2 on D1 of each cycle, plus, G-CSF 1PC sc qd, starting D7 until ANC recovery Ruxolitinib continuously given (D1-21) in the following dose schema&#xD;
Phase II Efficacy Study&#xD;
All patients received:&#xD;
Rituximab 375mg/m2 on D1 of each cycle, and Paclitaxel 200mg/m2 on D1 of each cycle, plus Ruxolitinib using RP2D daily on D1-21 G-CSF 1PC sc qd, starting D7 until ANC recovery&#xD;
Repeat every 21 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure</measure>
    <time_frame>1 year</time_frame>
    <description>The tumor response will be assessed according to IWG Response Criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Refractory Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ruxolitinib, paclitaxel, and rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab Paclitaxel Ruxolitinib</intervention_name>
    <description>Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>G-CSF 1PC sc qd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with relapsed/refractory CD20+ diffuse large B-cell lymphoma.&#xD;
&#xD;
          2. Age greater than 20 years and younger than 75 years old.&#xD;
&#xD;
          3. Measurable disease&#xD;
&#xD;
          4. Patients must have an ECOG performance status of less than or equal to 2.&#xD;
&#xD;
          5. Patients must have recovered from toxic effects of all prior therapy before entering&#xD;
             onto study.&#xD;
&#xD;
          6. A treatment of drug-free interval of at least 3 weeks since the last dose of&#xD;
             chemotherapy is required.&#xD;
&#xD;
          7. More than 4 weeks since prior radiotherapy is required.&#xD;
&#xD;
          8. Adequate bone marrow function&#xD;
&#xD;
          9. Adequate renal function with calculated glomerular filtration rate &gt; 15 mL/min&#xD;
&#xD;
         10. Patients must have adequate liver function&#xD;
&#xD;
         11. All patients must sign a document of informed consent indicating their awareness of&#xD;
             the investigational nature and the risks of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have prior treatment with ruxolitinib or taxane for DLBCL.&#xD;
&#xD;
          2. Pregnant or breast-feeding females.&#xD;
&#xD;
          3. Active or uncontrolled infection.&#xD;
&#xD;
          4. Life expectancy &lt; 6 months&#xD;
&#xD;
          5. Patients with brain or leptomeningeal metastases.&#xD;
&#xD;
          6. Known hypersensitivity to ruxolitinib or paclitaxel&#xD;
&#xD;
          7. Grade III peripheral neuropathy secondary to prior to therapy&#xD;
&#xD;
          8. Second malignancy, except indolent cancers not on active anti-cancer therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chih-Cheng Chen, M.D. Ph.D.</last_name>
    <phone>886-5-3621000</phone>
    <phone_ext>2852</phone_ext>
    <email>ccchen1968@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui-Jen Tsai, M.D. Ph.D.</last_name>
    <phone>886-6-7000123</phone>
    <phone_ext>65149</phone_ext>
    <email>hjtsai@nhri.edu.tw</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

